Task 108815
Melanotan II (10mg)
99.873% purity reported
Evidence cluster
Neuropeptide & Melanocortin Signalling
A model-aware cluster for Semax, Selank, melanocortin analogues and related fragments. It maps aliases carefully and avoids turning small or jurisdiction-specific studies into broad outcome claims.
Research frame
Questions this cluster is built to answer
- 01Are similarly named melanocortin compounds analytically and pharmacologically distinct?
- 02How large, accessible and independently replicated is the human evidence?
- 03Which statements come only from cell or animal systems?
Compound evidence records
Evidence dossier
KPV
A model-specific guide to KPV nomenclature and the mainly cellular and animal evidence surrounding this short alpha-MSH-derived tripeptide.
Open recordEvidence dossier
Selank
A guide to Selank identity and its narrow, geographically concentrated human literature, with explicit limits on generalisation.
Open recordEvidence dossier
Melanotan II
A safety-led guide to Melanotan II identity, small early human studies and the TGA's 2026 findings on unapproved, inconsistently dosed products.
Open recordEvidence dossier
PT-141 / Bremelanotide
A guide that maps the research code PT-141 to bremelanotide while separating authorised pharmaceutical evidence from unrelated catalogue material.
Open recordEstablished guide
Semax
Selected rat mechanism studies and a small human imaging study, with model-specific findings and limitations.
Open recordMethods and connected analysis
Research Insights
Oral vs Injectable Peptides: Why Formulation Changes the Evidence
Compare route, formulation and study context without treating every oral product or research vial as interchangeable.
Research Insights
Semax Research Guide: Animal Mechanisms and Human Imaging Evidence
Compare selected Semax studies by model and endpoint, separating rat BDNF and gene-expression work from a small human imaging study.
Document navigation
Published analytical records in this topic
Each record transcribes a published laboratory document and states its limits. A document is not treated as proof of the current inventory lot.
Task 123504
Semax (10mg)
99.290% purity reported
Task 123505
Selank (10mg)
99.877% purity reported
Task 124507
KLOW Peptide Blend (80mg)
4 composition results published
Catalogue context
Related public catalogue collections
These links organise public laboratory catalogue records by research subject. Catalogue availability is not evidence for a therapeutic outcome.